1 | medical device standards update | | | | | | | 5 | 0.21% |
2 | to parent navigation item | | | | | | | 5 | 0.21% |
3 | back to parent navigation | | | | | | | 5 | 0.21% |
4 | scientific advice in the | | | | | | | 4 | 0.16% |
5 | previous next regulatory rapporteur | | | | | | | 4 | 0.16% |
6 | − in conversation with | | | | | | | 4 | 0.16% |
7 | design and manufacture in | | | | | | | 4 | 0.16% |
8 | professionals in regulatory affairs | | | | | | | 4 | 0.16% |
9 | revolutionising the labelling landscape | | | | | | | 4 | 0.16% |
10 | sustainable design and manufacture | | | | | | | 4 | 0.16% |
11 | china drug master file | | | | | | | 4 | 0.16% |
12 | critical review and comparison | | | | | | | 4 | 0.16% |
13 | the processes when seeking | | | | | | | 4 | 0.16% |
14 | advice in the eu | | | | | | | 4 | 0.16% |
15 | next regulatory rapporteur – | | | | | | | 4 | 0.16% |
16 | in the eu and | | | | | | | 4 | 0.16% |
17 | eu and the usa | | | | | | | 4 | 0.16% |
18 | the eu and the | | | | | | | 4 | 0.16% |
19 | environmental risk assessment of | | | | | | | 4 | 0.16% |
20 | elabelling revolutionising the labelling | | | | | | | 3 | 0.12% |
21 | revises the guideline for | | | | | | | 3 | 0.12% |
22 | ema revises the guideline | | | | | | | 3 | 0.12% |
23 | regrappod − in conversation | | | | | | | 3 | 0.12% |
24 | sustainability imperative for the | | | | | | | 3 | 0.12% |
25 | of medicinal products for | | | | | | | 3 | 0.12% |
26 | risk assessment of medicinal | | | | | | | 3 | 0.12% |
27 | and the usa – | | | | | | | 3 | 0.12% |
28 | of the processes when | | | | | | | 3 | 0.12% |
29 | assessment of medicinal products | | | | | | | 3 | 0.12% |
30 | products for human use | | | | | | | 3 | 0.12% |
31 | medicinal products for human | | | | | | | 3 | 0.12% |
32 | for maximum residue limits | | | | | | | 3 | 0.12% |
33 | the relevance of sustainability | | | | | | | 3 | 0.12% |
34 | new approach methodologies for | | | | | | | 3 | 0.12% |
35 | assessment of medical devices | | | | | | | 3 | 0.12% |
36 | ema activities related to | | | | | | | 3 | 0.12% |
37 | artificial intelligence in drug | | | | | | | 3 | 0.12% |
38 | data protection for maximum | | | | | | | 3 | 0.12% |
39 | a the relevance of | | | | | | | 3 | 0.12% |
40 | review and comparison of | | | | | | | 3 | 0.12% |